JP6000245B2 - 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド - Google Patents

鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド Download PDF

Info

Publication number
JP6000245B2
JP6000245B2 JP2013521194A JP2013521194A JP6000245B2 JP 6000245 B2 JP6000245 B2 JP 6000245B2 JP 2013521194 A JP2013521194 A JP 2013521194A JP 2013521194 A JP2013521194 A JP 2013521194A JP 6000245 B2 JP6000245 B2 JP 6000245B2
Authority
JP
Japan
Prior art keywords
peptide
asicalgin
channel
pain
asic1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013521194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535965A5 (enExample
JP2013535965A (ja
Inventor
リングエグリア，エリック
ディオチョット，シルビィア
バロン‐フォスター，アン
サリーナ，ミグエル
ラズンスキー，ミシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2013535965A publication Critical patent/JP2013535965A/ja
Publication of JP2013535965A5 publication Critical patent/JP2013535965A5/ja
Application granted granted Critical
Publication of JP6000245B2 publication Critical patent/JP6000245B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013521194A 2010-07-26 2011-07-26 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド Active JP6000245B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1003136A FR2963010B1 (fr) 2010-07-26 2010-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic
FR1003136 2010-07-26
PCT/FR2011/051800 WO2012022894A1 (fr) 2010-07-26 2011-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic

Publications (3)

Publication Number Publication Date
JP2013535965A JP2013535965A (ja) 2013-09-19
JP2013535965A5 JP2013535965A5 (enExample) 2015-09-17
JP6000245B2 true JP6000245B2 (ja) 2016-09-28

Family

ID=43589927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013521194A Active JP6000245B2 (ja) 2010-07-26 2011-07-26 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド

Country Status (13)

Country Link
US (1) US8987207B2 (enExample)
EP (1) EP2598523B1 (enExample)
JP (1) JP6000245B2 (enExample)
CN (1) CN103097404B (enExample)
AU (1) AU2011290589A1 (enExample)
BR (1) BR112013001863A2 (enExample)
CA (1) CA2806471C (enExample)
FR (1) FR2963010B1 (enExample)
MX (1) MX336586B (enExample)
RU (1) RU2583299C2 (enExample)
SG (1) SG187877A1 (enExample)
WO (1) WO2012022894A1 (enExample)
ZA (1) ZA201300662B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105412932B (zh) * 2015-10-26 2019-08-16 上海交通大学医学院 含ASIC1a与RIP1结合抑制剂的制剂及其抑制神经元死亡的用途
CN112717135A (zh) * 2016-11-22 2021-04-30 上海交通大学医学院 酸敏感离子通道调控剂的用途
CN107384952A (zh) * 2017-08-23 2017-11-24 湖南甲骨文生物医药有限公司 用于筛选ASICs作用蛋白的酵母双杂交诱饵载体的构建方法
KR20220016891A (ko) * 2019-06-04 2022-02-10 상하이테크 유니버시티 친화성-성숙된 항-ASIC1a 항체
RU2768484C1 (ru) * 2021-05-24 2022-03-24 Закрытое акционерное общество "СКАЙ ЛТД" Фармацевтическая композиция иммуностимулирующих веществ мурамилпептидной природы

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776896A (en) 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
JP4959226B2 (ja) * 2006-05-19 2012-06-20 独立行政法人産業技術総合研究所 スリーフィンガー様蛋白質ライブラリ
JP2008193923A (ja) * 2007-02-09 2008-08-28 Janusys Kk 蛋白質ライブラリ

Also Published As

Publication number Publication date
RU2583299C2 (ru) 2016-05-10
EP2598523A1 (fr) 2013-06-05
US8987207B2 (en) 2015-03-24
SG187877A1 (en) 2013-03-28
US20130196923A1 (en) 2013-08-01
WO2012022894A4 (fr) 2012-04-12
FR2963010A1 (fr) 2012-01-27
CN103097404A (zh) 2013-05-08
CA2806471A1 (fr) 2012-02-23
CN103097404B (zh) 2015-09-16
ZA201300662B (en) 2013-09-25
BR112013001863A2 (pt) 2016-05-31
JP2013535965A (ja) 2013-09-19
WO2012022894A1 (fr) 2012-02-23
AU2011290589A1 (en) 2013-03-07
MX2013001020A (es) 2014-04-14
FR2963010B1 (fr) 2014-08-15
EP2598523B1 (fr) 2015-09-09
RU2013108262A (ru) 2014-09-10
CA2806471C (fr) 2020-07-07
MX336586B (es) 2016-01-21

Similar Documents

Publication Publication Date Title
Konradi et al. Amphetamine regulates gene expression in rat striatum via transcription factor CREB
AU2020281046B2 (en) Methods and compositions for improved cognition
JP6000245B2 (ja) 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド
EP0835126B1 (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
JP2010046088A (ja) 新規なぺプチド類
JP2003518477A (ja) 反応性酸素種およびフリーラジカルの効力を中和するための組成物および方法
US5482930A (en) Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
Ogawa et al. Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats
JP2002513380A (ja) コナントキンの使用
US20070173453A1 (en) Methods of preventing or treating brain ischemia or brain injury
JP2011522012A (ja) ペプチドトキシンＡＰＥＴｘ２の鎮痛作用
JP2001507924A (ja) コナントキン類
JP2021528390A (ja) ムスカリン受容体ｍ３に対して阻害活性を有するペプチド
JP2002509080A (ja) グラモストラ・スパチュラタの毒から得られる鎮痛性ペプチドおよびその使用
US6624288B1 (en) Gamma-conopeptides
JP2002526097A (ja) 新規なぺプチド類
KR20120122999A (ko) 알러지성 질환의 치료 및 예방을 위한 펩타이드
Pencheva et al. Antinociceptive effects of dalargin and analogues
Burlingame et al. Fainzilber et al.
HK1058146B (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150512

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160415

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160830

R150 Certificate of patent or registration of utility model

Ref document number: 6000245

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250